

**HARVARD PILGRIM HEALTH CARE
RECOMMENDED MEDICATION REQUEST GUIDELINES**

AFLIBERCEPT (EYLEA)

Generic	Brand	HICL	GCN	Exception/Other
AFLIBERCEPT	EYLEA		30919	

GUIDELINES FOR USE

1. Does the member have one of the following diagnoses?
 - Neovascular (Wet) age-related macular degeneration,
 - Diabetic macular edema (DME),
 - Diabetic retinopathy (DR) in patients with diabetic macular edema, or
 - Macular edema from retinal vein occlusion

If yes, **approve for 12 months by GPID up to 13 fills.** (Eylea is hard-coded for a quantity of two vials (two 0.05 ml vials) per 28 days. Please use status code #056 and the approval text provided.

APPROVAL TEXT: Your request has been approved for a 12-month period for a quantity up to two vials per 28 days.

If no, do not approve. Please use status code #238 and the denial text provided.

DENIAL TEXT: Per your health plan's Aflibercept (Eylea) guideline, the requested medication is only covered for patients with a diagnosis of neovascular (wet) age-related macular degeneration, diabetic macular edema, diabetic retinopathy in patients with diabetic macular edema, or macular edema from retinal vein occlusion. Your provider did not indicate that you have one of these conditions and therefore your request was not approved.

RATIONALE

Ensure appropriate diagnostic, utilization and safety criteria are used for the management of prior authorization requests for Eylea for diabetic macular edema, diabetic retinopathy with diabetic macular edema, established neovascular "wet" age-related macular degeneration, and macular edema from retinal vein occlusion.

FDA APPROVED INDICATIONS

- Neovascular (wet) age-related macular degeneration
- Macular edema following retinal vein occlusion
- Diabetic macular edema
- Diabetic retinopathy in patients with diabetic macular edema

Dosing:

Neovascular (Wet) Age - Related Macular Degeneration (AMD)

- The recommended dose for EYLEA is 2 mg (0.05mL) administered by intravitreal injection every 4 weeks (monthly) for the first 3 months followed by 2 mg (0.05 mL) via intravitreal injection once every 8 weeks (2 months). Although EYLEA may be dosed as frequently as 2mg every 4 weeks (monthly), additional efficacy was not demonstrated in most patients when EYLEA was dosed every 4 weeks compared to every 8 weeks. Some patients may need every 4 week (monthly) dosing after the first 12 weeks (3 months).

CONTINUED ON NEXT PAGE

**HARVARD PILGRIM HEALTH CARE
RECOMMENDED MEDICATION REQUEST GUIDELINES**

AFLIBERCEPT (EYLEA)

FDA APPROVED INDICATIONS (CONTINUED)

Macular Edema Following Retinal Vein Occlusion (RVO)

- The recommended dose for EYLEA is 2 mg (0.05 mL) administered by intravitreal injection once every 4 weeks (monthly).

Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR) in Patients with Diabetic Macular Edema

- The recommended dose for EYLEA is 2 mg (0.05 mL) administered by intravitreal injection every 4 weeks (monthly) for the first 5 injections followed by 2 mg (0.05 mL) via intravitreal injection once every 8 weeks (2 months). Although EYLEA may be dosed as frequently as 2mg every 4 weeks (monthly), additional efficacy was not demonstrated in most patients when EYLEA was dosed every 4 weeks compared to every 8 weeks. Some patients may need every 4 week (monthly) dosing after the first 20 weeks (5 months).

DOSAGE FORMS AND STRENGTHS

40 mg/mL solution for intravitreal injection in a single-use vial

REFERENCES

- Regeneron Pharmaceuticals Inc. Eylea (aflibercept) prescribing information. Tarrytown, NY. July 2015.
- Arroyo, JG. Age-related macular degeneration: Treatment and prevention. In: UpToDate, Post, TW (ed), Waltham, MA, 2015.
- Heier, JS., Brown, DM., Chong, V., et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. *Ophthalmology*. 2012; 119(12): 2537-48.
- Korobelnik, JF., Do, DV., Schmidt-Erfurth, U., et al. Intravitreal Aflibercept for Diabetic Macular Edema. *Ophthalmology*. 2014; 121(11): 2247-2254.
- Boyer, D., Heier, J., Brown, DM., et al. Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study. *Ophthalmology*. 2012; 119(5):1024-1032.
- Chang, AA., Hong, T., Ewe, SY., et al. The role of aflibercept in the management of diabetic macular edema. *Drug Des Devel Ther*. 2015; 9: 4389-96.
- Calvo, P., Abadia, B., Ferreras, A., et al. Diabetic Macular Edema: Options for Adjunct Therapy. *Drugs*. 2015 Aug 5. [epub ahead of print]
- Brown, DM., Schmidt-Erfurth, U., Do, DV., et al. Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. *Ophthalmology*. 2015, July 18. [epub ahead of print]
- Arcinue, CA., Ma, F., Barteselli, G., et al. One-year outcomes of aflibercept in recurrent or persistent neovascular age-related macular degeneration. *Am J Ophthalmol*. 2015; 159(3): 426-32.
- McKibbin, M., Devonport, H., Gale, R., et al. Aflibercept in wet AMD beyond the first hyear of treatment: recommendations by an expert roundtable panel. *Eye (Lond)*. 2015; 29 Suppl 1: S1-S11.
- Campa, C., Alivernini, G., Bolletta, E., et al. Anti-VEGF therapy for retinal vein occlusions. *Curr Drug Targets*. 2015 June 15. [epub ahead of pring]

Created: 03/16

Effective: 03/01/18

Client Approval: 01/31/18

P&T Approval: 09/11/17

Revised: 10/01/2018

Page 2